Agilent Technologies (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides instruments, software, services, and consumables for the entire laboratory workflow. Agilent's competitors include Thermo Fisher Scientific and PerkinElmer. On October 3, 2025, Jefferies set a price target of $130 for Agilent, while the stock was trading at $142.31, indicating a price difference of approximately -8.65% from the target.
Citi analysts recently held a "constructive" meeting with Agilent's management, highlighting growth drivers for the company into the next year. These factors are expected to translate into earnings leverage, as noted by the analysts. Agilent's management expressed confidence in the company's growth outlook for fiscal 2026, supported by strong margins in its fiscal fourth quarter of 2025 and fiscal 2026.
Agilent is well-positioned to benefit from strong topline and volume growth, the Ignite initiative, and easing tariff impacts. Citi analysts have maintained a 'Buy' rating on Agilent's stock, setting a target price of $165 per share. Despite this positive outlook, Agilent shares experienced a slight decline of 0.5%, closing at $137.96 on Thursday.
Currently, Agilent's stock is priced at $141.64, reflecting an increase of 2.12% or $2.94. Today, the stock has traded as low as $138.86 and as high as $143.09. Over the past year, the stock has reached a high of $153.84 and a low of $96.43. The company has a market capitalization of approximately $40.16 billion, with a trading volume of 1,916,720 shares on the NYSE.
